Abstract
Introduction: Stage III NSCLC is a heterogeneous disease requiring a multimodal management approach. We conducted a real-world, global study to characterize patients, treatment patterns, and their associated clinical outcomes for stage III NSCLC. Methods: KINDLE was a retrospective study in patients with stage III NSCLC (American Joint Committee on Cancer, seventh edition) diagnosed between January 2013 and December 2017, with at least 9 months of documented follow-up since index diagnosis. In addition to descriptive statistics, Kaplan-Meier methodology evaluated survival estimates; two-sided 95% confidence interval was computed. Cox proportional hazards model was used for univariate and multivariate analyses. Results: A total of 3151 patients from more than 100 centers across 19 countries from Asia, Middle East, Africa, and Latin America were enrolled. Median age was 63.0 years (range: 21.0–92.0); 76.5% were males, 69.2% had a smoking history, 53.7% had adenocarcinoma, and 21.4% underwent curative resection. Of greater than 25 treatment regimens, concurrent chemoradiotherapy was the most common (29.4%). The overall median progression-free survival (95% confidence interval) and median overall survival (mOS) were 12.5 months (12.06–13.14) and 34.9 months (32.00–38.01), respectively. Significant associations (p < 0.05) were observed for median progression-free survival and mOS with respect to sex, region, smoking status, stage, histology, and Eastern Cooperative Oncology Group status. In univariate and multivariate analyses, younger age, stage IIIA, better Eastern Cooperative Oncology Group status, concurrent chemoradiotherapy, and surgery as initial therapy predicted better mOS. Conclusions: KINDLE reveals the diversity in treatment practices and outcomes in stage III NSCLC in a real-world setting in the preimmuno-oncology era. There is a high unmet medical need, necessitating novel approaches to optimize outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 1733-1744 |
| Number of pages | 12 |
| Journal | Journal of Thoracic Oncology |
| Volume | 16 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2021 Oct |
Bibliographical note
Funding Information:The study was funded by AstraZeneca . The authors thank Ms. Prajakta Nachane (M. Pharm.), Covance Scientific Services & Solutions Pvt., Ltd., for medical writing support that was funded by AstraZeneca in accordance with good pharmacoepidemiology practices 3 guidelines ( http://www.ismpp.org/gpp3 ).
Funding Information:
The study was funded by AstraZeneca. The authors thank Ms. Prajakta Nachane (M. Pharm.), Covance Scientific Services & Solutions Pvt. Ltd. for medical writing support that was funded by AstraZeneca in accordance with good pharmacoepidemiology practices 3 guidelines (http://www.ismpp.org/gpp3). Disclosure: Dr. Jazieh reports receiving research support from AstraZeneca, Merck Sharp & Dohme, and Pfizer and travel support from Bristol-Myers Squibb and AstraZeneca. Dr. Tan reports having advisory role and serving as consultant for Novartis, Bayer, Boehringer Ingelheim, Celgene, AstraZeneca, Eli Lilly, and Loxo Oncology; receiving travel support and honorarium from Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche, and Takeda Pharmaceuticals; and receiving research funding from Novartis, AstraZeneca, GlaxoSmithKline, Bayer, and Pfizer. Dr. Soo reports being on advisory board for Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda Pharmaceuticals, and Yuhan; and receiving research grant support from AstraZeneca and Boehringer Ingelheim. Dr. Prabhash reports receiving research funding from Alkem Laboratories, BDR Pharmaceutics, Biocon, Dr. Reddy's Laboratories, Fresenius Kabi, Natco Pharma, and Roche. Mr. Kumar reports having employment (full time) in AstraZeneca Pharma India Ltd. Dr. Huggenberger reports having employment (full time) in AstraZeneca Plc.; and stock ownership for AstraZeneca, TG Therapeutics, Chinook Therapeutics, and Adaptimmune Therapeutics. Dr. Robb reports having employment (full time) in AstraZeneca Plc. Dr. Cho reports receiving research funding from Novartis, Bayer, AstraZeneca, Mogam Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono Pharmaceuticals, Dizal Pharma, Merck Sharp & Dohme, AbbVie, Medpacto, GI Innovation, Eli Lilly, Blueprint Medicines, and Interpark Bio Convergence Corp.; having consulting role for Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Ono Pharmaceuticals, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, Merck Sharp & Dohme, Janssen, Medpacto, and Blueprint Medicines; having stock ownership for TheraCanVac Inc., Gencurix Inc., Bridgebio Therapeutics, Kanaph Therapeutic Inc., Cyrus Therapeutics, and Interpark Bio Convergence Corp.; being on scientific advisory board for Kanaph Therapeutic Inc., Brigebio Therapeutics, Cyrus Therapeutics, and Guardant Health; serving as board of director for Gencurix Inc. and Interpark Bio Convergence Corp.; having royalty for Champions Oncology; and serving as founder for DAAN Biotherapeutics. Dr. Onal declares no conflict of interest.
Publisher Copyright:
© 2021 International Association for the Study of Lung Cancer
All Science Journal Classification (ASJC) codes
- Oncology
- Pulmonary and Respiratory Medicine
